Financial Performance - Q1 2025 - Net sales decreased by $6.2 million, a 5.2% decrease, to $112.0 million compared to $118.2 million in Q1 2024[30] - Adjusted Cost of Products Sold as a percentage of sales improved by 360 basis points, from 37.2% in Q1 2024 to 33.6% in Q1 2025[30] - Adjusted EBITDA increased by $5.1 million, a 41% increase, to $17.6 million compared to $12.5 million in Q1 2024[30] - Adjusted EPS increased by $0.19, a 238% increase, to $0.27 compared to $0.08 in Q1 2024[30] - Cash and Cash Equivalents decreased by $8.2 million, from $75.0 million as of December 31, 2024, to $66.8 million[30] Financial Outlook - FY 2025 - Net sales are projected to be in the range of $445 million to $460 million, representing a reported growth of -1% to 2% and constant currency (CC) growth of flat to 3%[32] - Adjusted EBITDA is projected to be in the range of $65 million to $70 million, representing a reported growth of 8% to 17% and CC growth of 8% to 17%[32] - Adjusted EPS is projected to be in the range of $0.80 to $0.95, representing a reported growth of 29% to 53% and CC growth of 31% to 55%[32] Portfolio Revitalization - The company is revitalizing its portfolio with recent launches in dental implants, biomaterials, and digital dentistry[23] - Recent launches include TSX® and T3® PRO Immediate Molar Implant Systems, Azure Multi-Platform Solutions Portfolio, and RealGUIDE® 5.4 Software[23, 24, 25] Digital Dentistry Adoption - The company is seeing rapid adoption of guided surgery software, with 39% growth in FY24[29]